바이오헤이븐 (BHVN) 주가 전망: 목표주가, 배당, 최신 뉴스

Biohaven Ltd. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.

It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.

The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors.

In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus.

The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Biohaven Ltd.는 면역학, 신경과학 및 종양학 치료제의 발견·개발·상용화에 주력하는 바이오제약회사입니다. 본사는 코네티컷주 뉴헤이븐에 있으며 2022년에 법인 설립되었고, 이전 명칭은 Biohaven Research Ltd.였으며 2022년 9월 현재 명칭으로 변경했습니다.

주요 임상 파이프라인으로는 BHV-1300(그레이브스병·류마티스 관절염 용, 임상 2상), BHV-1400(IgA 신증 치료용, 임상 2상), BHV-1600(주산기 심근병증 치료용, 임상 1상), BHV-8000(파킨슨병 치료용, 임상 3상), Opakalim(국소성 간질 치료용, 임상 3상), BHV-2100(통증 장애 치료용, 임상 2상) 및 BHV-2000(비만 치료용, 임상 2상)이 있습니다. 또한 진행성 또는 전이성 상피성 종양용 BHV-1510(임상 2상)과 요로상피암 등 종양용 BHV-1530(임상 2상)도 개발 중입니다.

비임상(전임상) 파이프라인에는 BHV-1310(중증근무력증), BHV-1320(면역매개질환), BHV-1450(Pemphigus·MuSK 관련 중증근무력증·LGI-1 뇌염), BHV-1420(막성 신병증), BHV-1440(그레이브스병 및 갑상선 안병증[TED]), BHV-6500(제1형 당뇨병), BHV-1490(IgM 신경병증 및 Waldenström 거대단백혈증), BHV-8100(신경퇴행성 질환) 및 BHV-1955(이명) 등이 포함되어 있습니다.

• 주소: 215 Church Street, New Haven, CT 06510, United States

• 전화번호: 203 404 0410

• 웹사이트: https://www.biohaven.com

• 섹터: Healthcare

• 산업: Biotechnology

• 직원 수: 274